Dual activities of PAF in central nervous system and its values in development of new drugs

Abstract

Abstract: Platelet-activating factor (PAF), an endogenous bioactive lipid generated by phospholipase A2 and other pathways, displays a variety of biological activities in the nervous system.It has been suggested that PAF plays important roles in neuronal physiological functions including acting as a retrograde messenger to enhance synapse plasticity and memory formation, via activation of its specific membrane receptors.Therefore, the drugs that mimic the action of PAF or modulate the production and inactivation of PAF maybe promising in memory-enhancing.However, under certain pathological conditions, such as Alzheimer' s disease, HIV-associated dementia or post-ischemic neuronal death, acting as a potent inflammatory mediator and neurotoxin, PAF has been implicated in the pathophysiology of brain injury.So, modulating the metabolism and effects of PAF (e.g., blocking the PAF receptor) may become important strategies of intervention of Alzheimer' s disease, HIV-associated dementia or postischemic neuronal death.

Key words: platelet activating factor, learning and memory, long-term potentiation, Alzheimer' s disease, HIV-associated dementia, cerebral ischemia

CLC Number:

R969

LI Juan, CHEN Hong-zhuan. Dual activities of PAF in central nervous system and its values in development of new drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(3): 270-274.

References

1 Prescott SM, Zimmerman GA, Stafforini DM, et al.Platelet-activating factor and related lipid mediators[J].Annu Rev Biochem, 2000;69:419-445.
2 Snyder F, Fitzgerald V, Blank ML.Biosynthesis of platelet-activating factor and enzyme inhibitors[J].Adv Exp Med Biol, 1996;416:5-10.
3 Stafforini DM, McIntyre TM, Zimmerman GA, et al.Platelet-activating factor, a pleiotrophic mediator of phy siological and pathological processes[J].Crit Rev Clin Lab Sci, 2003;40:643-672.
4 Aihara M, Ishii S, Kume K, et al.Interaction between neurone and microglia mediated by platelet-activating factor[J].Genes Cells, 2000;5:397-406.
5 Mori M, Aihara M, Kume K, et al.Predominant expression of platelet-activating factor receptor in the rat brain microglia[J]. Neurosci, 1996;16:3590-3600.
6 Chen C, Bazan NG.Lipid signaling:Sleep, synaptic plasticity, and neuroprotection [J].Prostaglandins Other Lipid Mediat, 2005;77:65-76.
7 Kornecki E,Wieraszko A, Chan J, et al.Platelet activating factor (PAF) in memory formation:role as a retrograde messenger in long-term potentiation[J].J LipidMediat Cell Signal, 1996;14: 115-126.
8 Kato K, Clark GD, Bazen NG, et al.Platelet-activating factor as a potential retrograde messenger in CA1 hippocampal long-term potentiation[J].Nature, 1994;367:175-179.
9 Izquierdo I, Fin C, Schmitz PK, et al.Memory enhancement by intrahippocampal, intraamygdala, or intraentorhinal infusion of platelet-activating factor measured in an inhibitory avoidance task[J].Proc Natl Acad Sci USA, 1995;92:5047-5051.
10 Chen C, Magee JC, Marcheselli V, et al.Attenuated LTP in hippocampal dentate gyrus neurons of mice deficient in the PAF receptor[J].J Neurophysiol, 2001;85:384-390.
11 Bazan NG.The neuromessenger platelet-activating factor in plasticity and neurodegeneration[J].Prog Brain Res, 1998;118: 281-291.
12 Bate C, Salmona M, Williams A.The role of platelet activating factor in prion and amyloid-β neurotoxicity[J].Neuroreport, 2004;15:509-513.
13 Xu Y, Tao YX.Involvement of the NMDA receptor nitric/oxide signal pathway in platelet-activating factor-induced neurotoxicity [J].NeuroReport, 2004;15:263-266.
14 Sattay aprasert P, Choi HB, Ryu JK, et al.Platelet-activating factor mediated inflammatory cytokine expression in human microglia[J].J Neurochem, 2004;88:P19-P21.
15 HershkowitzM, Adunsky A.Binding of platelet-activating factor to platelets of Alzheimer' s disease and multiinfarct dementia patients[J].Neurobioly Aging, 1996;17:865-868.
16 Perry SW, Hamilton JA, Tjoelker LW, et al.Platelet-activating factor receptor activation.An initiator step in HIV-1 neuropathogenesis[J].J Bio Chem, 1998;273:17660-17664.
17 Persidsky Y, Gendelman HE.Murine models for human immunodeficiency virus type 1-associated dementia:the development of new treatment testing paradigms[J].J Neurovirol, 2002;8:49-52.
18 Schifitto G, Sacktor N,Marder K, et al.Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment[J].Neurology, 1999;53:391-396.
19 Nishida K,Markey SP.Platelet-activating factor in brain regions after transient ischemia in gerbils[J].Stroke, 1996;27:514-519.
20 Adunsky A, HershkowitzM, Atar E.Infarct volume, neurological severity and PAF binding to platelets of patients with acute cerebral ischemic stroke[J].Neurol Res, 1999;21:645-648.
21 Wood PL.Microglia as a unique cellular target in the treatment of stroke:potential neurotoxic mediators produced by activated microglia[J].Neurol Res, 1995;17:242-248.
22 Liu XH, Eun BL, Barks JD.Platelet-activating factor antagonist BN 50730 attenuates hypoxic-ischemic brain injury in neonatal rats[J].Pediatr Res, 2001;49:804-811.
23 Park TS, Gonzales ER, Gidday JM.Platelet-activating factor mediates ischemia-induced leukocyte-endothelial adherence in newborn pig brain[J].J Cereb Blood Flow Metab, 1999;19:417-424.
24 SarafMK, Kishore K, Thomas KM, et al.Role of platelet activating factor in triazolobenzodiazepines-induced retrograde amnesia[J].Behav Brain Res, 2003;142:31-40.
25 Li J, Huang H, Miezan Ezoulin JM, et al.Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonististic activity[J].Int J Neuropsy chopharmacol, 2007;10:21-29.

[1]	Qin LiYang. Effects of rapamycin intervention during pregnancy on cognitive function of autism model in rat offspring [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 841-847.
[2]	YUAN Li, HAN Lingna, CHANG Yongli, ZHANG Cuiying. Study on GIP analogues against the cognitive impairments in APP/PS1 transgenic mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 721-729.
[3]	XIAO Shigeng, DONG Wenbin, YE Xiaodi, CHEN Aiying, CHENG Min, MIAO Yunping, ZHENG Gaoli. Effects of autophagy on the protection of minocycline against cerebral ischemia-reperfusion injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 730-736.
[4]	YU Chenchen, LIU Shuqun, LIU Jianlong, CAO Hong, LIU Xuejiao, CAI Xixi. Effects of curcumin on injury in hippocampal neurons and expression of blood corticosterone and SGK1 in hippocampal during global cerebral ischemia-reperfusion injury in hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 737-743.
[5]	DUAN Jinning, XIANG Changqing, QIAN Aihong, LI Jin, CHEN Xiuquan, HAN Yongfeng, HUANG Na, FAN Lili. Saponins from Rhizoma Panacis Majoris protect against cerebral ischemia and reperfusion injury through modulation of PI3K/Akt signaling pathway in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 750-758.
[6]	LIU Xiaoyan, TIAN Ye, LIU Jifei, SU Gang, ZHANG Zhenchang. Research progress on the protective mechanisms of curcumin on cerebral ischemia-reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1305-1309.
[7]	WU Caixia, DU Guanhua. Effects of pinocembrin on mRNA expression of genes related to endoplasmic reticulum stress-mediated apoptosis in acute injury induced by focal cerebral ischemia-reperfusion [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 34-40.
[8]	ZHU Jiejin, WU Yong, YE Xiaoli, YE Huajin, WANG Gang, FEI Fei. Effect of fisetin on learning and memory impairment induced by cerebral ischemia reperfusion and HPA axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1002-1007.
[9]	WEI Huiming, MA Weiqing, LI Wenfeng, WANG Huiming. Effect of antagonist of NR2A-containing N-methyl-D-aspartate receptors on synaptic long-term potentiation in hippocampus in rats with neuropathic pain [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1008-1011.
[10]	SHEN Chen, LI Yunman, XIA Nian, XU Dan, HAN Dan, CHEN Shijie. Research on the inhibition of Treg cells on MMP-9 in rheumatoid arthritis with acute cerebral ischemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 831-840.
[11]	XIE Yuewu, ZHANG Fang, GUO Yan. Correlation between cerebral blood flow and infarct volume of the middle cerebral artery occlusion in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 501-506.
[12]	LI Rui, LUO Shengyong. Protective effects of Longxuetongluo capsule on cerebral ischemia injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1232-1236.
[13]	FAN Kaiyu，WANG Bing，MEI Xiaole，CHEN Zhiwu. Protective effects of total flavonoids of Chuzhou chrysanthemum against cerebral ischemia- reperfusion injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 9-12.
[14]	CHEN Chuang. Protection and mechanism of extract of Phyllanthus emblica L. on focal cerebral ischemia-reperfusion injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 991-994.
[15]	WU Chang-jiang, HUANG Chao-fa, ZHU Tuan-jie, WANG Hui. Effects of exogenous H₂S donor NaHS on learning and memory in rats after cardiopulmonary resuscitation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 727-732.